SlideShare uma empresa Scribd logo
1 de 42
Baixar para ler offline
3RD UNIT
ANTI-HYPERLIPIDEMIC
AGENTS
Prepared by
G. Nikitha, M.Pharmacy
Assistant Professor
Department of Pharmaceutical Chemistry
Sree Dattha Institute Of Pharmacy
Hyderabad
1
Subject: Medicinal Chemistry-II
Year: B.Pharmacy 3rd Year
Semister: 1st Semister
CONTENTS
 Introduction.
 Classification .
 Drugs used in Anti Hyperlipidaemics Agents
 Mechanism of action .
 SAR.
 Structure
 Adverse Drug Reactions .
 Uses.
2
INTRODUCTION
 Lipids are naturally fat like components of cells in the body.
 Although body synthesis the required amount of lipids additional
amount is derived from food and can be harmful.
 These plasma lipids are water insoluble and hence need to
transported through carriers known as lipoproteins.
 An increase in lipid particularly cholesterol a condition involving
damage of heart.
3
Lipoproteins are of 4 types:
 High density lipoprotein (HDL)
 Low density lipoprotein (LDL)
 Intermediate density lipoprotein (IDL)
 Very low density lipoprotein (VLDL)
4
CLASSIFICATION
1. HMG-COA reductase inhibitors:
5
Simvatain
Metastatin
Lovastatin
6
Pravastatin Atorvastatin
Rosuvastatin
2. Fabric acid derivative:
7
Clofibrate Gemfibrozil
8
benzafibrate
Fenofinrate
Ciprofribrate
3. Bile acid Sequestrantes
9
Cholestyramine
Colestipol
4. Inhibition of LDL oxidation
10
Probucol
5. Lypolysis/ Triglyceride synthesis inhibitor
Nicotinic acid
6. Miscellaneous drugs
11
Ezetimibe
Dextrothyroxine
β-sitosterol
7. New Drugs
12
Patavastain
HMG-COA REDUCTASE INHIBITORS
13
1. HMG-COA reductase inhibitors:
This class of drug is known to be the most efficient and best
tolerated among all other antihyerlipidaemic drugs.
Mechanism of action:
Cholesterol is synthesizes in the liver by the conversion of 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) to mevalonic
acid by the enzyme HMG-CoA reductase. Statins act by inhibiting
this rate limiting enzyme, thereby resulting in reduced hepatic
cholesterol synthesis. This in turn results in compensatory increase
in synthesis of high affinity LDL receptors on the surface of liver
cells and consequent increase in the uptake and catabolism of
plasma IDL and LDL. Thus a significant decrease in plasma LDL
cholesterol levels is achieved. 14
SAR of HMG-COA reductase inhibitors :
 Mevastatin and Lovastatin are the lead compounds in the
development of HMGRIs.
 Lactone ring, bicyclic rings Ethylene Bridge are very important for
the activity.
 Provastatin is the ring opened dihydroxyacid with a 6 hydroxyl
group is more hydrophilic. So it has the low penetration to the
peripheral tissues and less side effects.
15
Common for all statins
 The 3,5 dihydroxycarboxylate is essential for inhibitory activity.
Compounds containing a lactone are prodrugs requiring in vivo
hydrolysis.
 The absolute stereochemistry of the 3-and 5-hydroxyl groups must
be same as the Mevastatin and Lovastatin.
 A double bound between C6 and C7 can either increase or decrease
activity. The ethyl group provides optimal activity for compounds
containing ring A and some heterocyclic rings (pyrrole ring of
atorvastatin). The ethenyl group is optimal for compounds with other
rings such as indole and pyrimidine rings seen in fluvastatin and
cerivastatin.
16
 Ring A sub class- the decline ring is essential for anchoring the
compound to the enzyme active site. Replacement with the
cyclohexane ring resulted in 10,000 fold decrease in activity.
 Stereochemistry of the ester chain is important for activity, the
conversion of this ester to an ether resulted in a decrease in activity.
 Methyl substitution at R2 position increases activity (simvastatin is
more potent than Lovastatin).
 β hydroxyl group substitution at R1 position enhances
hydrophilicity and provides some cellular specificity. 17
 Ring B sub class- either zero or one (five or six member
heterocyclic).
 The para-flurophenyl cannot be coplanar with the central aromatic
ring. (Structural restraints to cause coplanarity have resulted in a loss
of activity).
 R substitution with aryl groups of hydrocarbon chains enhances
lipophilicity and inhibitory activity.
18
Pharmacokinetics:
All strains of oral administration get absorbed to the extent of 40-
90% except fluvastatin which is completely absorbed. Lovastatin
and simvastatin are prodrugs which get hydrolysed to active
metabolites in the GIT while atorvastatin, fluvastine, rosuvastatin are
fluorinated compounds which are activate drugs. All statins undergo
first pass metabolism and excreted mainly through bile.
Adverse Drug Reactions:
 Nausea, headache, rashes, and bowel upset
 Sleep disturbances
 Memory loss, impotence, gynaecomatia, peripheral neuropathy
 Liver damage
19
Therapeutic Uses:
 Statins are useful in both primary and secondary
hypercholesterolaemia. They cause reduction in the progression of
atherosclerotic lesions and occurrence of myocardial infarction.
 Statins are the first line drugs for primary hyperlipidaemics which
increased LDL and total cholesterol level.
 They are used to reduce the incidence of myocardial infarction in
patients
20
Lovastatin
Structure:
IUPAC: 8-{2-[-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-
hexahydronaphthalen-1-yl -2-methylbutanoate
Properties:
white or almost white crystalline powder, insoluble in water, soluble
in acetone and sparingly soluble in ethanol, practically insoluble
in hexane.
21
Molecular formula: C24H36O5
Pharmacokinetics:
Oral route of administration, Lovastatin is given as a lactone prodrug
and thus, in order to produce its mechanism of action, it is required
to be converted to the active beta-hydroxy form. This drug activation
process does not seem to be related to CYP isoenzyme activity. but
rather to be controlled by the activity of serum paraoxonase,
Following an oral dose of 14C-labeled lovastatin to man, 10% of the
dose was excreted in urine and 83% in feces. The latter represents
absorbed drug excreted in bile, together with unabsorbed drug.
Adverse Drug Reactions:
 pain in your stomach area, constipation
 Nausea, headache
 Heartburn, memory loss/forgetfulness
 weakness/lack of energy, muscle pain
 Confusion, inability to fall asleep 22
Therapeutic Uses:
 Lovastatin is used to decrease the amount of cholesterol and other
fatty substances in your blood.
 If cholesterol builds up in your arteries, it may block the flow of
blood to your heart, brain, or other parts of your body. This raises
your risk of serious problems, such as a heart attack or stroke.
Lowering your cholesterol level lowers these risks
Dose:
10-80 mg/ day
23
FABRIC ACID DERIVATIVE
24
2. Fabric acid derivative
This groups of drugs are derivatives of fibric acid like isobutyric acid
and include gemfibrozil, benzafibrate, fenofibrate.
Mechanism of action:
 These are known to simulate the nuclear transcription receptor called
peroxisome proliferator activated receptor-α (PPAR-α) which
controls the expressions of genes mediating triglyceride metabolism.
 They enhance the activity of lipoprotein lipase (LPL) which is
responsible for the hydrolysis of VLDL triglycerides. Hence
incorporation of fatty acids into VLDL in the liver is decreased and
there by synthesis and secretion of VLDL is inhibited.
25
SAR of Fabric acid derivative:
 Isobutyric acid group is essential for activity.
 Compounds containing an ester, such as clofibrate and fenofibrate
are prodrugs and require in vivo hydrolysis.
 Substitution at para position of the aromatic ring with a chloro group
or a chlorine containing isopropyl ring produce compound with
significantly longer half life.
 Most of drugs contain a phenoxyisobutyric acid, the addition of an
m-propyl spacer as seen in gemfibrozil results in an active drug.
26
Pharmacokinetics:
They are completely absorbed from the gastrointestinal tract. They
mostly exist in protein bound form and are mainly excreted in an
unchanged through urine.
Adverse Drug Reactions:
 Allergic reactions, nausea, diarrhea are common side effects.
 Weight gain
 Increase in serum amino transferases or alkaline phosphatase levels
and reversible myopathy have also reported.
 Chronic therapy may increases the risk of gall stone formation.
27
Therapeutic Uses:
 Fibrates are the first line drugs used in the treatment of
hypertriglyceridaemic especially those associated with low HDL-C
level.
 They are effective in decreasing genetic hypertriglyceridaemic and
dysbetalipoproteinaemia.
 They are also effective in treating familial combined
hypertriglyceridaemia and hyperlipidaemics associated with type-2
diabetes.
28
Clofibrate
Structure:
IUPAC: ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
Properties:
Colorless to pale yellow liquid, faint characteristic odor, faint
characteristic taste, insoluble in water, soluble in alcohol,
chloroform, miscible with acetone and ether.
29
Molecular Formula: C12H15ClO3
Pharmacokinetics:
Oral route of administration, Hepatic and gastrointestinal: rapid de-
esterification occurs in the gastrointestinal tract and/or on first-pass
metabolism to produce the active form, clofibric acid (chlorophenoxy
isobutyric acid [CPIB]), eliminated through urine.
Adverse Drug Reactions:
 Head ache, Nausea , Vomiting
 Fever
 Blood in urine
 Sweating of feet
 Increase of appetite, Stomach pain, gastric problems
 Weight gain
 Chest pain
30
Therapeutic Uses:
 Used in the treatment of III, IV, V hyperlipidaemics
 They are also effective in treating familial combined
hypertriglyceridaemia and hyperlipidaemics associated with type-2
diabetes.
Dose:
5 to 2 grams a day. This is divided into two to four doses.
31
BILE ACID SEQUESTRANTES
32
3. Bile acid Sequestrantes
Mechanism of actions:
They are insoluble non-absorbable basic anion exchange resins
which bind with bile acids and form insoluble complexes in the
intestine which gets excreted in faces.
Adverse Drug Reactions:
 Head ache, Vomiting
 Constipation, Heart burn are common
Therapeutic Uses:
 Cholestyramine is used as an anti-hyperlipidaemic in children and
pregnant women.
 It is also used in treating pruritus associated with biliary cirrhosis
and cholestatic jaundice. 33
SAR of Bile acid Sequestrantes:
 Cholestyramine is a copolymer consisting primarily of polystyrene
with small amount of divinyl benzene as a cross linking agent.
 In addition it contains some fixed quaternary ammonium groups.
 These positively charged groups function as binding sites for anions.
 Colestipol is a copolymer of tetraethylenepentamine and
epichlorhydrin. It contains basic secondary and tertiary amines.
 Total nitrogen content of Colestipol is greater than Cholestyramine
the functional ion exchange capacity of the resin depends upon
intestinal pH and may be less than Cholestyramine.
 The adsorption capacity of Cholestyramine for bile salts is more
than the Colestipol.
34
Cholestyramine
Structure:
IUPAC: [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium
Properties:
White or almost white fine powder, hygroscopic insoluble in water,
methylene chloride, ethanol.
35
Molecular Formula: C21H30ClN
Pharmacokinetics:
Oral route of administration, metabolized through bile acids.
Cholestyramine resin adsorbs and combines with the bile acids in
the intestine to form an insoluble complex which is excreted in the
feces.
Adverse Drug Reactions:
 Constipation.
 Upset stomach or stomach pain.
 Diarrhea or loose stools.
 Nausea.
 Vomiting.
 Belching.
 Loss of appetite.
 Skin irritation.
36
Therapeutic Uses:
Cholestyramine is used to reduce high cholesterol levels. It's given to
people with high cholesterol who haven't been able to lower their
cholesterol enough with diet changes. This drug is also used to treat
itching due to partial bile obstruction.
Dose:
4 to 16g/day
37
Colestipol
Structure:
IUPAC: N'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-
diamine;hydrochloride
Properties:
Yellow to orange beads, hygroscopic in nature, it does not dissolve
in water, dilute aqueous solution of acids and alkali, insoluble in
ethanol, dichloromethane. 38
Molecular Formula:C8H24ClN5
Pharmacokinetics:
 Oral route of administration, Colestipol hydrochloride binds bile
acids in the intestine forming a complex that is then ultimately
excreted in the feces. In humans, less than 0.17% of a single 14C-
labeled colestipol hydrochloride dose is excreted in the urine when
given following 60 days of chronic dosing of 20 grams of colestipol
hydrochloride per day.
 The increased fecal loss of bile acids due to colestipol hydrochloride
administration leads to increased oxidation of cholesterol to bile
acids, it is not absorbed into the systemic circulation nor is it
hydrolyzed by any digestive enzymes. Its action is ultimately limited
to the lumen of the gastrointestinal tract, where it is eventually
passed into the feces
39
Adverse Drug Reactions:
 Constipation, Diarrhea
 stomach/abdominal pain, gas,
 Nausea and vomiting may occur.
 Weakness
 Confusion
 Rashes
Therapeutic Uses:
 It is used along with a proper diet to lower cholesterol in
the blood. Lowering cholesterol helps decrease the risk for strokes
and heart attacks.
Dose:
5-30 mg day
40
Reference books
 Text book of Medicinal chemistry volume-1-3rd edition by
V.Alagarasamy.
 Text book of Medicinal chemistry volume-2-3rd edition by
V.Alagarasamy.
 Medicinal chemistry by Rama Rao Nadendla.
41
THANK YOU
42

Mais conteúdo relacionado

Mais procurados

Congestive heart failure (chf) medicinal chemistry
Congestive heart failure (chf) medicinal chemistryCongestive heart failure (chf) medicinal chemistry
Congestive heart failure (chf) medicinal chemistryTushar Morankar
 
Thyroid and antithyroid drugs- medicinal chemistry
Thyroid and antithyroid drugs- medicinal chemistryThyroid and antithyroid drugs- medicinal chemistry
Thyroid and antithyroid drugs- medicinal chemistryDr Duggirala Mahendra
 
Antidiabetic agents-medicinal chemistry
Antidiabetic agents-medicinal chemistryAntidiabetic agents-medicinal chemistry
Antidiabetic agents-medicinal chemistryDr Duggirala Mahendra
 
Prostaglandins,Angiotensin,Bradykinin-Dr.Jibachha Sah,M.V.Sc,Lecturer
Prostaglandins,Angiotensin,Bradykinin-Dr.Jibachha Sah,M.V.Sc,LecturerProstaglandins,Angiotensin,Bradykinin-Dr.Jibachha Sah,M.V.Sc,Lecturer
Prostaglandins,Angiotensin,Bradykinin-Dr.Jibachha Sah,M.V.Sc,LecturerDr. Jibachha Sah
 
Antihyperlipidemic agents
Antihyperlipidemic agentsAntihyperlipidemic agents
Antihyperlipidemic agentskencha swathi
 
Industrial production, estimation and utilization of phytoconstituents
Industrial production, estimation and utilization of phytoconstituentsIndustrial production, estimation and utilization of phytoconstituents
Industrial production, estimation and utilization of phytoconstituentsMahewash Sana Pathan
 
Utilization of radioactive isotopes in the investigation of biogenetic studies
Utilization of radioactive isotopes in the investigation of biogenetic studiesUtilization of radioactive isotopes in the investigation of biogenetic studies
Utilization of radioactive isotopes in the investigation of biogenetic studiesMs. Pooja Bhandare
 
Medicinal chemistry, sympathomimetic agents, unit-2 ,4th sem
Medicinal chemistry, sympathomimetic agents, unit-2 ,4th semMedicinal chemistry, sympathomimetic agents, unit-2 ,4th sem
Medicinal chemistry, sympathomimetic agents, unit-2 ,4th semsnigdharanibehera
 
Medicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agentsMedicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agentsDHARMENDRA BARIA
 
3rd unit drugs used in congestive heart faliure
3rd unit drugs used in congestive heart faliure3rd unit drugs used in congestive heart faliure
3rd unit drugs used in congestive heart faliureNikithaGopalpet
 
Isolation,identification and analysis of phytoconstituents. Dr.U.Srinivasa, P...
Isolation,identification and analysis of phytoconstituents. Dr.U.Srinivasa, P...Isolation,identification and analysis of phytoconstituents. Dr.U.Srinivasa, P...
Isolation,identification and analysis of phytoconstituents. Dr.U.Srinivasa, P...Srinivas college of pharmacy, Mangalore
 
Local Anesthetics-medicinal chemistry
Local  Anesthetics-medicinal chemistryLocal  Anesthetics-medicinal chemistry
Local Anesthetics-medicinal chemistryDr Duggirala Mahendra
 
4th unit drugs for erectile dysfunction
4th unit drugs for erectile dysfunction4th unit drugs for erectile dysfunction
4th unit drugs for erectile dysfunctionNikithaGopalpet
 
Sar of phenothiazine by sirajuddin
Sar of phenothiazine by sirajuddinSar of phenothiazine by sirajuddin
Sar of phenothiazine by sirajuddinsirajuddin56
 
Adrenergic Drugs synthesis
Adrenergic Drugs synthesisAdrenergic Drugs synthesis
Adrenergic Drugs synthesisDrParthiban1
 

Mais procurados (20)

Congestive heart failure (chf) medicinal chemistry
Congestive heart failure (chf) medicinal chemistryCongestive heart failure (chf) medicinal chemistry
Congestive heart failure (chf) medicinal chemistry
 
Thyroid and antithyroid drugs- medicinal chemistry
Thyroid and antithyroid drugs- medicinal chemistryThyroid and antithyroid drugs- medicinal chemistry
Thyroid and antithyroid drugs- medicinal chemistry
 
Antidiabetic agents-medicinal chemistry
Antidiabetic agents-medicinal chemistryAntidiabetic agents-medicinal chemistry
Antidiabetic agents-medicinal chemistry
 
Prostaglandins,Angiotensin,Bradykinin-Dr.Jibachha Sah,M.V.Sc,Lecturer
Prostaglandins,Angiotensin,Bradykinin-Dr.Jibachha Sah,M.V.Sc,LecturerProstaglandins,Angiotensin,Bradykinin-Dr.Jibachha Sah,M.V.Sc,Lecturer
Prostaglandins,Angiotensin,Bradykinin-Dr.Jibachha Sah,M.V.Sc,Lecturer
 
Antihyperlipidemic agents
Antihyperlipidemic agentsAntihyperlipidemic agents
Antihyperlipidemic agents
 
Industrial production, estimation and utilization of phytoconstituents
Industrial production, estimation and utilization of phytoconstituentsIndustrial production, estimation and utilization of phytoconstituents
Industrial production, estimation and utilization of phytoconstituents
 
Utilization of radioactive isotopes in the investigation of biogenetic studies
Utilization of radioactive isotopes in the investigation of biogenetic studiesUtilization of radioactive isotopes in the investigation of biogenetic studies
Utilization of radioactive isotopes in the investigation of biogenetic studies
 
Sympathomimmetic agents
Sympathomimmetic agentsSympathomimmetic agents
Sympathomimmetic agents
 
Medicinal chemistry, sympathomimetic agents, unit-2 ,4th sem
Medicinal chemistry, sympathomimetic agents, unit-2 ,4th semMedicinal chemistry, sympathomimetic agents, unit-2 ,4th sem
Medicinal chemistry, sympathomimetic agents, unit-2 ,4th sem
 
Sex hormones - Medicinal Chemistry
Sex hormones - Medicinal ChemistrySex hormones - Medicinal Chemistry
Sex hormones - Medicinal Chemistry
 
Medicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agentsMedicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agents
 
3rd unit drugs used in congestive heart faliure
3rd unit drugs used in congestive heart faliure3rd unit drugs used in congestive heart faliure
3rd unit drugs used in congestive heart faliure
 
Cholinergic agent
Cholinergic agentCholinergic agent
Cholinergic agent
 
1 st unit h2 antagonist
1 st unit h2 antagonist1 st unit h2 antagonist
1 st unit h2 antagonist
 
Isolation,identification and analysis of phytoconstituents. Dr.U.Srinivasa, P...
Isolation,identification and analysis of phytoconstituents. Dr.U.Srinivasa, P...Isolation,identification and analysis of phytoconstituents. Dr.U.Srinivasa, P...
Isolation,identification and analysis of phytoconstituents. Dr.U.Srinivasa, P...
 
Local Anesthetics-medicinal chemistry
Local  Anesthetics-medicinal chemistryLocal  Anesthetics-medicinal chemistry
Local Anesthetics-medicinal chemistry
 
4th unit drugs for erectile dysfunction
4th unit drugs for erectile dysfunction4th unit drugs for erectile dysfunction
4th unit drugs for erectile dysfunction
 
Sar of phenothiazine by sirajuddin
Sar of phenothiazine by sirajuddinSar of phenothiazine by sirajuddin
Sar of phenothiazine by sirajuddin
 
Antianginal drugs
Antianginal drugsAntianginal drugs
Antianginal drugs
 
Adrenergic Drugs synthesis
Adrenergic Drugs synthesisAdrenergic Drugs synthesis
Adrenergic Drugs synthesis
 

Semelhante a 3rd unit anti-hyperlipidemic agents ppt

Anti hyperlipidemic agents ppt
Anti hyperlipidemic agents ppt Anti hyperlipidemic agents ppt
Anti hyperlipidemic agents ppt Indraj Saini
 
Antihyperlipidemic Agent
Antihyperlipidemic Agent Antihyperlipidemic Agent
Antihyperlipidemic Agent Anamikasingh405
 
" Anti-Hyperlipidemic Agents/Drugs "
" Anti-Hyperlipidemic Agents/Drugs "" Anti-Hyperlipidemic Agents/Drugs "
" Anti-Hyperlipidemic Agents/Drugs "Bhavesh Amrute
 
antihyperlipidemic drugs.pptx
antihyperlipidemic drugs.pptxantihyperlipidemic drugs.pptx
antihyperlipidemic drugs.pptxRCharulatha4
 
Antihyperlipidemic drugs
Antihyperlipidemic drugsAntihyperlipidemic drugs
Antihyperlipidemic drugsLikhita Kolli
 
Pharmacology of Hypolipidaemics drugs
Pharmacology of Hypolipidaemics drugsPharmacology of Hypolipidaemics drugs
Pharmacology of Hypolipidaemics drugsKoppala RVS Chaitanya
 
Antihyperlipidimic drug therapy-current and noval approaches.pptx
Antihyperlipidimic drug therapy-current and noval approaches.pptxAntihyperlipidimic drug therapy-current and noval approaches.pptx
Antihyperlipidimic drug therapy-current and noval approaches.pptxMohammedObaidMohiudd
 
Hyperlipidemia and its treatment
Hyperlipidemia and its treatment Hyperlipidemia and its treatment
Hyperlipidemia and its treatment Komal Rajgire
 
AntiHyperlipidaemic Agents 1.pptx
AntiHyperlipidaemic Agents 1.pptxAntiHyperlipidaemic Agents 1.pptx
AntiHyperlipidaemic Agents 1.pptxSameena Ramzan
 
Hypolipidemic drugs
Hypolipidemic drugsHypolipidemic drugs
Hypolipidemic drugsajaykumarbp
 
Drugs for hyperlipidiemia
Drugs for hyperlipidiemiaDrugs for hyperlipidiemia
Drugs for hyperlipidiemiaJITHIN MATHEW
 
Assignment hypolipidimcs
Assignment hypolipidimcsAssignment hypolipidimcs
Assignment hypolipidimcsHimanshu Rajput
 

Semelhante a 3rd unit anti-hyperlipidemic agents ppt (20)

Anti hyperlipidemic agents ppt
Anti hyperlipidemic agents ppt Anti hyperlipidemic agents ppt
Anti hyperlipidemic agents ppt
 
Antihyperlipidemic Agent
Antihyperlipidemic Agent Antihyperlipidemic Agent
Antihyperlipidemic Agent
 
Antihyperlipidemic drug
Antihyperlipidemic drugAntihyperlipidemic drug
Antihyperlipidemic drug
 
hyperlipidemic drugs..pptx
hyperlipidemic drugs..pptxhyperlipidemic drugs..pptx
hyperlipidemic drugs..pptx
 
" Anti-Hyperlipidemic Agents/Drugs "
" Anti-Hyperlipidemic Agents/Drugs "" Anti-Hyperlipidemic Agents/Drugs "
" Anti-Hyperlipidemic Agents/Drugs "
 
antihyperlipidemic drugs.pptx
antihyperlipidemic drugs.pptxantihyperlipidemic drugs.pptx
antihyperlipidemic drugs.pptx
 
Antihyperlipidemic drugs
Antihyperlipidemic drugsAntihyperlipidemic drugs
Antihyperlipidemic drugs
 
Pharmacology of Hypolipidaemics drugs
Pharmacology of Hypolipidaemics drugsPharmacology of Hypolipidaemics drugs
Pharmacology of Hypolipidaemics drugs
 
Antihyperlipidimic drug therapy-current and noval approaches.pptx
Antihyperlipidimic drug therapy-current and noval approaches.pptxAntihyperlipidimic drug therapy-current and noval approaches.pptx
Antihyperlipidimic drug therapy-current and noval approaches.pptx
 
Ppt hyperlipidimic
Ppt hyperlipidimicPpt hyperlipidimic
Ppt hyperlipidimic
 
Hyperlipidemia and its treatment
Hyperlipidemia and its treatment Hyperlipidemia and its treatment
Hyperlipidemia and its treatment
 
AntiHyperlipidaemic Agents 1.pptx
AntiHyperlipidaemic Agents 1.pptxAntiHyperlipidaemic Agents 1.pptx
AntiHyperlipidaemic Agents 1.pptx
 
lipid lowering agents
lipid lowering agentslipid lowering agents
lipid lowering agents
 
Hypolipidaemic drugs
Hypolipidaemic drugsHypolipidaemic drugs
Hypolipidaemic drugs
 
Hypolipidemic drugs
Hypolipidemic drugsHypolipidemic drugs
Hypolipidemic drugs
 
Drugs for hyperlipidiemia
Drugs for hyperlipidiemiaDrugs for hyperlipidiemia
Drugs for hyperlipidiemia
 
Hypolipidemic drugs
Hypolipidemic drugsHypolipidemic drugs
Hypolipidemic drugs
 
Assignment hypolipidimcs
Assignment hypolipidimcsAssignment hypolipidimcs
Assignment hypolipidimcs
 
Anti-Hyperlipidemic Drugs (Pharmacology -II) By- Anshik Srivastava.pdf
Anti-Hyperlipidemic Drugs (Pharmacology -II) By- Anshik Srivastava.pdfAnti-Hyperlipidemic Drugs (Pharmacology -II) By- Anshik Srivastava.pdf
Anti-Hyperlipidemic Drugs (Pharmacology -II) By- Anshik Srivastava.pdf
 
Treatment of hyperlipidemia.pptx
Treatment of hyperlipidemia.pptxTreatment of hyperlipidemia.pptx
Treatment of hyperlipidemia.pptx
 

Mais de NikithaGopalpet

12. acidifying reagents or acidifiers
12. acidifying reagents or acidifiers12. acidifying reagents or acidifiers
12. acidifying reagents or acidifiersNikithaGopalpet
 
7.complexometric titrations
7.complexometric titrations7.complexometric titrations
7.complexometric titrationsNikithaGopalpet
 
6. precipitation titrations
6. precipitation titrations6. precipitation titrations
6. precipitation titrationsNikithaGopalpet
 
5. non aqueous titrations
5. non aqueous titrations5. non aqueous titrations
5. non aqueous titrationsNikithaGopalpet
 
Alkalimetry and acidimetry
Alkalimetry and acidimetryAlkalimetry and acidimetry
Alkalimetry and acidimetryNikithaGopalpet
 
Pharmaceutical inorganic chemistry introduction
Pharmaceutical inorganic chemistry introductionPharmaceutical inorganic chemistry introduction
Pharmaceutical inorganic chemistry introductionNikithaGopalpet
 
Formulation and evaluation of oral fast dissolving films of project
Formulation and evaluation of oral fast dissolving films of projectFormulation and evaluation of oral fast dissolving films of project
Formulation and evaluation of oral fast dissolving films of projectNikithaGopalpet
 
5th unit local anaesthetics
5th unit local anaesthetics5th unit local anaesthetics
5th unit local anaestheticsNikithaGopalpet
 
5th unit anti- diabetic agents
5th unit anti- diabetic agents5th unit anti- diabetic agents
5th unit anti- diabetic agentsNikithaGopalpet
 
4th unit corticosteroids
4th unit corticosteroids4th unit corticosteroids
4th unit corticosteroidsNikithaGopalpet
 
4th unit drugs acting on endocrine system
4th unit drugs acting on endocrine system4th unit drugs acting on endocrine system
4th unit drugs acting on endocrine systemNikithaGopalpet
 

Mais de NikithaGopalpet (20)

1 st unit antibiotics
1 st unit antibiotics1 st unit antibiotics
1 st unit antibiotics
 
11. medicinal gases
11. medicinal gases11. medicinal gases
11. medicinal gases
 
12. acidifying reagents or acidifiers
12. acidifying reagents or acidifiers12. acidifying reagents or acidifiers
12. acidifying reagents or acidifiers
 
10. limit tests
10. limit tests10. limit tests
10. limit tests
 
9.gravimetric analysis
9.gravimetric analysis9.gravimetric analysis
9.gravimetric analysis
 
8. theory of indicators
8. theory of indicators8. theory of indicators
8. theory of indicators
 
7.complexometric titrations
7.complexometric titrations7.complexometric titrations
7.complexometric titrations
 
6. precipitation titrations
6. precipitation titrations6. precipitation titrations
6. precipitation titrations
 
5. non aqueous titrations
5. non aqueous titrations5. non aqueous titrations
5. non aqueous titrations
 
Alkalimetry and acidimetry
Alkalimetry and acidimetryAlkalimetry and acidimetry
Alkalimetry and acidimetry
 
4. redox titrations
4. redox titrations4. redox titrations
4. redox titrations
 
2. volumetric analysis
2. volumetric analysis2. volumetric analysis
2. volumetric analysis
 
3. acid base titrations
3. acid base titrations3. acid base titrations
3. acid base titrations
 
1. errors ppt
1. errors ppt1. errors ppt
1. errors ppt
 
Pharmaceutical inorganic chemistry introduction
Pharmaceutical inorganic chemistry introductionPharmaceutical inorganic chemistry introduction
Pharmaceutical inorganic chemistry introduction
 
Formulation and evaluation of oral fast dissolving films of project
Formulation and evaluation of oral fast dissolving films of projectFormulation and evaluation of oral fast dissolving films of project
Formulation and evaluation of oral fast dissolving films of project
 
5th unit local anaesthetics
5th unit local anaesthetics5th unit local anaesthetics
5th unit local anaesthetics
 
5th unit anti- diabetic agents
5th unit anti- diabetic agents5th unit anti- diabetic agents
5th unit anti- diabetic agents
 
4th unit corticosteroids
4th unit corticosteroids4th unit corticosteroids
4th unit corticosteroids
 
4th unit drugs acting on endocrine system
4th unit drugs acting on endocrine system4th unit drugs acting on endocrine system
4th unit drugs acting on endocrine system
 

Último

How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17Celine George
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.EnglishCEIPdeSigeiro
 
Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfMohonDas
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational PhilosophyShuvankar Madhu
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxheathfieldcps1
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxAditiChauhan701637
 
UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024UKCGE
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptxraviapr7
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfMohonDas
 
The Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsThe Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsEugene Lysak
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxKatherine Villaluna
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxMYDA ANGELICA SUAN
 
Education and training program in the hospital APR.pptx
Education and training program in the hospital APR.pptxEducation and training program in the hospital APR.pptx
Education and training program in the hospital APR.pptxraviapr7
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxKatherine Villaluna
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRATanmoy Mishra
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapitolTechU
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfTechSoup
 
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxPISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxEduSkills OECD
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...raviapr7
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17Celine George
 

Último (20)

How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.
 
Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdf
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational Philosophy
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptx
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptx
 
UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdf
 
The Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsThe Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George Wells
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptx
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptx
 
Education and training program in the hospital APR.pptx
Education and training program in the hospital APR.pptxEducation and training program in the hospital APR.pptx
Education and training program in the hospital APR.pptx
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptx
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
 
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxPISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17
 

3rd unit anti-hyperlipidemic agents ppt

  • 1. 3RD UNIT ANTI-HYPERLIPIDEMIC AGENTS Prepared by G. Nikitha, M.Pharmacy Assistant Professor Department of Pharmaceutical Chemistry Sree Dattha Institute Of Pharmacy Hyderabad 1 Subject: Medicinal Chemistry-II Year: B.Pharmacy 3rd Year Semister: 1st Semister
  • 2. CONTENTS  Introduction.  Classification .  Drugs used in Anti Hyperlipidaemics Agents  Mechanism of action .  SAR.  Structure  Adverse Drug Reactions .  Uses. 2
  • 3. INTRODUCTION  Lipids are naturally fat like components of cells in the body.  Although body synthesis the required amount of lipids additional amount is derived from food and can be harmful.  These plasma lipids are water insoluble and hence need to transported through carriers known as lipoproteins.  An increase in lipid particularly cholesterol a condition involving damage of heart. 3
  • 4. Lipoproteins are of 4 types:  High density lipoprotein (HDL)  Low density lipoprotein (LDL)  Intermediate density lipoprotein (IDL)  Very low density lipoprotein (VLDL) 4
  • 5. CLASSIFICATION 1. HMG-COA reductase inhibitors: 5 Simvatain Metastatin Lovastatin
  • 7. 2. Fabric acid derivative: 7 Clofibrate Gemfibrozil
  • 9. 3. Bile acid Sequestrantes 9 Cholestyramine Colestipol
  • 10. 4. Inhibition of LDL oxidation 10 Probucol 5. Lypolysis/ Triglyceride synthesis inhibitor Nicotinic acid
  • 14. 1. HMG-COA reductase inhibitors: This class of drug is known to be the most efficient and best tolerated among all other antihyerlipidaemic drugs. Mechanism of action: Cholesterol is synthesizes in the liver by the conversion of 3- hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) to mevalonic acid by the enzyme HMG-CoA reductase. Statins act by inhibiting this rate limiting enzyme, thereby resulting in reduced hepatic cholesterol synthesis. This in turn results in compensatory increase in synthesis of high affinity LDL receptors on the surface of liver cells and consequent increase in the uptake and catabolism of plasma IDL and LDL. Thus a significant decrease in plasma LDL cholesterol levels is achieved. 14
  • 15. SAR of HMG-COA reductase inhibitors :  Mevastatin and Lovastatin are the lead compounds in the development of HMGRIs.  Lactone ring, bicyclic rings Ethylene Bridge are very important for the activity.  Provastatin is the ring opened dihydroxyacid with a 6 hydroxyl group is more hydrophilic. So it has the low penetration to the peripheral tissues and less side effects. 15
  • 16. Common for all statins  The 3,5 dihydroxycarboxylate is essential for inhibitory activity. Compounds containing a lactone are prodrugs requiring in vivo hydrolysis.  The absolute stereochemistry of the 3-and 5-hydroxyl groups must be same as the Mevastatin and Lovastatin.  A double bound between C6 and C7 can either increase or decrease activity. The ethyl group provides optimal activity for compounds containing ring A and some heterocyclic rings (pyrrole ring of atorvastatin). The ethenyl group is optimal for compounds with other rings such as indole and pyrimidine rings seen in fluvastatin and cerivastatin. 16
  • 17.  Ring A sub class- the decline ring is essential for anchoring the compound to the enzyme active site. Replacement with the cyclohexane ring resulted in 10,000 fold decrease in activity.  Stereochemistry of the ester chain is important for activity, the conversion of this ester to an ether resulted in a decrease in activity.  Methyl substitution at R2 position increases activity (simvastatin is more potent than Lovastatin).  β hydroxyl group substitution at R1 position enhances hydrophilicity and provides some cellular specificity. 17
  • 18.  Ring B sub class- either zero or one (five or six member heterocyclic).  The para-flurophenyl cannot be coplanar with the central aromatic ring. (Structural restraints to cause coplanarity have resulted in a loss of activity).  R substitution with aryl groups of hydrocarbon chains enhances lipophilicity and inhibitory activity. 18
  • 19. Pharmacokinetics: All strains of oral administration get absorbed to the extent of 40- 90% except fluvastatin which is completely absorbed. Lovastatin and simvastatin are prodrugs which get hydrolysed to active metabolites in the GIT while atorvastatin, fluvastine, rosuvastatin are fluorinated compounds which are activate drugs. All statins undergo first pass metabolism and excreted mainly through bile. Adverse Drug Reactions:  Nausea, headache, rashes, and bowel upset  Sleep disturbances  Memory loss, impotence, gynaecomatia, peripheral neuropathy  Liver damage 19
  • 20. Therapeutic Uses:  Statins are useful in both primary and secondary hypercholesterolaemia. They cause reduction in the progression of atherosclerotic lesions and occurrence of myocardial infarction.  Statins are the first line drugs for primary hyperlipidaemics which increased LDL and total cholesterol level.  They are used to reduce the incidence of myocardial infarction in patients 20
  • 21. Lovastatin Structure: IUPAC: 8-{2-[-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl- hexahydronaphthalen-1-yl -2-methylbutanoate Properties: white or almost white crystalline powder, insoluble in water, soluble in acetone and sparingly soluble in ethanol, practically insoluble in hexane. 21 Molecular formula: C24H36O5
  • 22. Pharmacokinetics: Oral route of administration, Lovastatin is given as a lactone prodrug and thus, in order to produce its mechanism of action, it is required to be converted to the active beta-hydroxy form. This drug activation process does not seem to be related to CYP isoenzyme activity. but rather to be controlled by the activity of serum paraoxonase, Following an oral dose of 14C-labeled lovastatin to man, 10% of the dose was excreted in urine and 83% in feces. The latter represents absorbed drug excreted in bile, together with unabsorbed drug. Adverse Drug Reactions:  pain in your stomach area, constipation  Nausea, headache  Heartburn, memory loss/forgetfulness  weakness/lack of energy, muscle pain  Confusion, inability to fall asleep 22
  • 23. Therapeutic Uses:  Lovastatin is used to decrease the amount of cholesterol and other fatty substances in your blood.  If cholesterol builds up in your arteries, it may block the flow of blood to your heart, brain, or other parts of your body. This raises your risk of serious problems, such as a heart attack or stroke. Lowering your cholesterol level lowers these risks Dose: 10-80 mg/ day 23
  • 25. 2. Fabric acid derivative This groups of drugs are derivatives of fibric acid like isobutyric acid and include gemfibrozil, benzafibrate, fenofibrate. Mechanism of action:  These are known to simulate the nuclear transcription receptor called peroxisome proliferator activated receptor-α (PPAR-α) which controls the expressions of genes mediating triglyceride metabolism.  They enhance the activity of lipoprotein lipase (LPL) which is responsible for the hydrolysis of VLDL triglycerides. Hence incorporation of fatty acids into VLDL in the liver is decreased and there by synthesis and secretion of VLDL is inhibited. 25
  • 26. SAR of Fabric acid derivative:  Isobutyric acid group is essential for activity.  Compounds containing an ester, such as clofibrate and fenofibrate are prodrugs and require in vivo hydrolysis.  Substitution at para position of the aromatic ring with a chloro group or a chlorine containing isopropyl ring produce compound with significantly longer half life.  Most of drugs contain a phenoxyisobutyric acid, the addition of an m-propyl spacer as seen in gemfibrozil results in an active drug. 26
  • 27. Pharmacokinetics: They are completely absorbed from the gastrointestinal tract. They mostly exist in protein bound form and are mainly excreted in an unchanged through urine. Adverse Drug Reactions:  Allergic reactions, nausea, diarrhea are common side effects.  Weight gain  Increase in serum amino transferases or alkaline phosphatase levels and reversible myopathy have also reported.  Chronic therapy may increases the risk of gall stone formation. 27
  • 28. Therapeutic Uses:  Fibrates are the first line drugs used in the treatment of hypertriglyceridaemic especially those associated with low HDL-C level.  They are effective in decreasing genetic hypertriglyceridaemic and dysbetalipoproteinaemia.  They are also effective in treating familial combined hypertriglyceridaemia and hyperlipidaemics associated with type-2 diabetes. 28
  • 29. Clofibrate Structure: IUPAC: ethyl 2-(4-chlorophenoxy)-2-methylpropanoate Properties: Colorless to pale yellow liquid, faint characteristic odor, faint characteristic taste, insoluble in water, soluble in alcohol, chloroform, miscible with acetone and ether. 29 Molecular Formula: C12H15ClO3
  • 30. Pharmacokinetics: Oral route of administration, Hepatic and gastrointestinal: rapid de- esterification occurs in the gastrointestinal tract and/or on first-pass metabolism to produce the active form, clofibric acid (chlorophenoxy isobutyric acid [CPIB]), eliminated through urine. Adverse Drug Reactions:  Head ache, Nausea , Vomiting  Fever  Blood in urine  Sweating of feet  Increase of appetite, Stomach pain, gastric problems  Weight gain  Chest pain 30
  • 31. Therapeutic Uses:  Used in the treatment of III, IV, V hyperlipidaemics  They are also effective in treating familial combined hypertriglyceridaemia and hyperlipidaemics associated with type-2 diabetes. Dose: 5 to 2 grams a day. This is divided into two to four doses. 31
  • 33. 3. Bile acid Sequestrantes Mechanism of actions: They are insoluble non-absorbable basic anion exchange resins which bind with bile acids and form insoluble complexes in the intestine which gets excreted in faces. Adverse Drug Reactions:  Head ache, Vomiting  Constipation, Heart burn are common Therapeutic Uses:  Cholestyramine is used as an anti-hyperlipidaemic in children and pregnant women.  It is also used in treating pruritus associated with biliary cirrhosis and cholestatic jaundice. 33
  • 34. SAR of Bile acid Sequestrantes:  Cholestyramine is a copolymer consisting primarily of polystyrene with small amount of divinyl benzene as a cross linking agent.  In addition it contains some fixed quaternary ammonium groups.  These positively charged groups function as binding sites for anions.  Colestipol is a copolymer of tetraethylenepentamine and epichlorhydrin. It contains basic secondary and tertiary amines.  Total nitrogen content of Colestipol is greater than Cholestyramine the functional ion exchange capacity of the resin depends upon intestinal pH and may be less than Cholestyramine.  The adsorption capacity of Cholestyramine for bile salts is more than the Colestipol. 34
  • 35. Cholestyramine Structure: IUPAC: [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium Properties: White or almost white fine powder, hygroscopic insoluble in water, methylene chloride, ethanol. 35 Molecular Formula: C21H30ClN
  • 36. Pharmacokinetics: Oral route of administration, metabolized through bile acids. Cholestyramine resin adsorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the feces. Adverse Drug Reactions:  Constipation.  Upset stomach or stomach pain.  Diarrhea or loose stools.  Nausea.  Vomiting.  Belching.  Loss of appetite.  Skin irritation. 36
  • 37. Therapeutic Uses: Cholestyramine is used to reduce high cholesterol levels. It's given to people with high cholesterol who haven't been able to lower their cholesterol enough with diet changes. This drug is also used to treat itching due to partial bile obstruction. Dose: 4 to 16g/day 37
  • 38. Colestipol Structure: IUPAC: N'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2- diamine;hydrochloride Properties: Yellow to orange beads, hygroscopic in nature, it does not dissolve in water, dilute aqueous solution of acids and alkali, insoluble in ethanol, dichloromethane. 38 Molecular Formula:C8H24ClN5
  • 39. Pharmacokinetics:  Oral route of administration, Colestipol hydrochloride binds bile acids in the intestine forming a complex that is then ultimately excreted in the feces. In humans, less than 0.17% of a single 14C- labeled colestipol hydrochloride dose is excreted in the urine when given following 60 days of chronic dosing of 20 grams of colestipol hydrochloride per day.  The increased fecal loss of bile acids due to colestipol hydrochloride administration leads to increased oxidation of cholesterol to bile acids, it is not absorbed into the systemic circulation nor is it hydrolyzed by any digestive enzymes. Its action is ultimately limited to the lumen of the gastrointestinal tract, where it is eventually passed into the feces 39
  • 40. Adverse Drug Reactions:  Constipation, Diarrhea  stomach/abdominal pain, gas,  Nausea and vomiting may occur.  Weakness  Confusion  Rashes Therapeutic Uses:  It is used along with a proper diet to lower cholesterol in the blood. Lowering cholesterol helps decrease the risk for strokes and heart attacks. Dose: 5-30 mg day 40
  • 41. Reference books  Text book of Medicinal chemistry volume-1-3rd edition by V.Alagarasamy.  Text book of Medicinal chemistry volume-2-3rd edition by V.Alagarasamy.  Medicinal chemistry by Rama Rao Nadendla. 41